Oxidized-LDL/β2-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes

American Journal of Clinical Pathology

Volumn 133, Issue 5, 2010, Pages 737-743

  Greco, Thomas P ^a,b   Conti Kelly, Ann Marie ^a   Anthony, J Robert ^a   Greco Jr , Thomas ^a   Doyle, Robin ^a   Boisen, Matt ^c   Kojima, Kazuo ^d   Matsuura, Eiji ^e   Lopez, Luis R ^c  

^a ST MARY S HOSPITAL   (United States)

^b YALE UNIVERSITY   (United States)

^c Corgenix ^*  (United States)

^d Medical & Biological Laboratories Co Ltd   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

2 glycoprotein I; Atherosclerosis; Coronary artery disease; Oxidized low density lipoprotein

Indexed keywords

BETA2 GLYCOPROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOGRAPHY; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; ANGIOCARDIOGRAPHY; BLOOD; COHORT ANALYSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE; RISK FACTOR;

ACUTE CORONARY SYNDROME; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS;

EID: 77951912176     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP88WVRDRDFBAS     Document Type: Article

References (38)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1153-11143
3. Lindahl B, Toss H, Siegbahn B, et al. Markers of myocardial damage and inflammation in relation to long-term morbidity and unstable coronary heart disease. N Engl J Med. 2001;343:1139-1147.
4. Packard CJ, O'Reilly DS, Caslake MJ. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2001;343:1148-1155.
5. Folsom AR, Chambless LE, Ballantyne CM. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med. 2006;166:1368-1373.
6. Rodgers G, Kopecky S. The future of cardiovascular biomarkers. Am Heart Hosp J. 2006;4:228-231.
7. Lloyd-Jones DM, Tian L. Predicting cardiovascular risk. Arch Intern Med. 2006;166:1342-1344.
8. DeLemos J, Lloyd-Jones D. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008;358:2172-2174. (Pubitemid 351679606)
9. Shlipak MG, Ix JH, Bibbins-Domingo K, et al. Biomarkers to predict recurrent cardiovascular disease: The Heart and Soul Study. Am J Med. 2008;121:50-57.
10. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795.
11. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation and genetics. Circulation. 1995;91:2488-2496.
12. Virella G, Atchley DH, Koskinen S, et al. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002;105:81-92. (Pubitemid 35222245)
13. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
14. Steinberg D. Low density lipoprotein oxidation and its pathobiologial significance. J Biol Chem. 1997;272:20963-20966. (Pubitemid 27373946)
15. Meisinger C, Baumert J, Khuseyinova N, et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112:651-657. (Pubitemid 41099043)
16. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complication and human serum paraoxonase in patients with type 2 diabetes. Metabolism. 2004;53:297-302. (Pubitemid 38684688) (Pubitemid 38684688)
17. Tsimikas S, Brilakais ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary heart disease. N Engl J Med. 2005;353:46-57.
18. 2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low-density lipoproteins by macrophages. J Lipid Res. 2001;42:697-709.
19. 2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res. 2002;43:1486-1495.
20. 2-glycoprotein I function in health and disease. Thromb Res. 2004;114:35-46.
21. Ames PRJ, Alves J, Murat I, et al. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology. 1999;38:529-534.
22. 2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol. 2004;121:426-436.
23. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic disease. Circulation. 2005;112:3337-3347.
24. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol. 2005;25:1776-1785.
25. 2-glycoprotein I: implications as an atherogenic autoantigen. J Lipid Res. 2003;44:716-726.
26. 2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999;99:2227-2230.
27. Greco TP, Conti-Kelly AM, Greco T Jr, et al. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol. 2009;132:613-620.
28. 2-glycoprotein I complexes in type 2 diabetes mellitus. Ann N Y Acad Sci. 2005;1051:97-103.
29. 2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract. 2004;98:c15-c24.
30. Van Berkel TJ, De Rijke YB, Kruijt JK. Different fate in vivo of oxidatively modified low-density lipoprotein and acetylated low-density lipoprotein in rats: recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem. 1991;266:2282-2289.
31. Lopez LR, Buckner TR, Hurley BL, et al. Determination of oxidized low-density lipoproteins (oxLDL) versus oxLDL/β2GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann N Y Acad Sci. 2007;1109:303-310.
32. Fong LG, Parthasarathy S, Witztum JL, et al. Nonenzymatic oxidative cleavage of peptides bonds in apoprotein B-100. J Lipid Res. 1987;28:1466-1477. (Pubitemid 18025879)
33. Esterbauer H, Jurgens G, Quehenberger O, et al. Autoxidation of human low-density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res. 1987;28:495-509.
34. Matsuura E, Kobayashi K, Tabuchi M, et al. Oxidative modification of low-density lipoproteins and immune regulation of atherosclerosis. Prog Lipid Res. 2006;45:466-486.
35. 2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus. 2005;14:736-741.
36. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
37. 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost. 2007;5:2421-2428.
38. Neville C, Rauch J, Kassiss J, et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost. 2009;101:100-107.